2020 On-site introduces new solutions for delayed clinical trials
Category: #health  By Pankaj Singh  Date: 2020-06-19
  • share
  • Twitter
  • Facebook
  • LinkedIn

2020 On-site introduces new solutions for delayed clinical trials

The COVID-19 pandemic has significantly impacted the existing ecosystem of clinical trials as a whole. Except for COVID-19, most of the on-going or new clinical studies have essentially delayed or stopped in several countries across the world.

In a bid to streamline the clinical trial ecosystem involving ophthalmic endpoints, 2020 On-site, the America-based provider of on-site vision care for schools and businesses, has reportedly expanded its convenience-based eye care service to include an exclusive solution for investors, trail sponsors, sites, patients, and investigators.

According to sources, to prevent delays in clinical trials, 2020 On-site is offering a truly patient-centric solution for clinical trials involving ophthalmic endpoints. The company’s professionals and optometrists will visit patients in their homes anywhere in America, offering a safe and flexible way for the continuation of clinical trials.

Moreover, the company’s expertise in securely collecting vital optometric data, patient care, and cutting-edge IT systems with built-in redundancies will ensure the integrity of every clinical trial. Its logistics capabilities will also help its mobile clinicians to visit patients across the nation in just a few days.

Speaking on which, Alexis McLaughlin, CEO of 2020 On-site said that clinical trials are vital to aid the advancement of novel medicines and the company’s mobile clinic can conveniently meet the demand. The company believes that on-site mobile service for clinical care may become the new standard for some treatments or patients, Mr. McLaughlin added.

For the record, established in 2014 in Boston, the company offers on-site optometry services through cutting-edge mobile vision clinics. 2020 On-site introduced its new service in May and deployed its mobile clinic to aid a nationwide clinical study for a major biotechnology company. Since then, it has traversed around 8,000 miles to visit patients in 12 states.

Source Credit -https://uk.finance.yahoo.com/news/2020-launches-first-direct-patient-185400396.html

 



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Dada Group partners with Ferrero for new snack food retail model
Dada Group partners with Ferrero for new snack food retail model
By Pankaj Singh

The new retail model will help Ferrero improve brand reach to younger online customers in China

Chinese on-demand delivery and retail platform, Dada Group has inked...

Aphena Pharma to complete expansion of Solid Dose Division by April
Aphena Pharma to complete expansion of Solid Dose Division by April
By Pankaj Singh

Aphena Pharma Solutions, a pharmaceutical services provider, has reportedly announced the continuous expansion of its Tennessee-based Solid Dose Division worth $21 million. This division is expected to be completed by ...

Canada-based CloudMD buys CMD to expand medical database
Canada-based CloudMD buys CMD to expand medical database
By Pankaj Singh

CloudMD Software & Services Inc., a virtual medical care solutions provider based in Canada, has reportedly announced that it has completed the acquisition of the Canadian Medical Directory (CMD)- the nation’...